Skip to content

Clinical observation and comparison of hydroquinone, microneedle and picosecond laser in the treatment of melasma

A randomized self split-face controlled study: Clinical observation and comparison of hydroquinone, microneedle and picosecond laser in the treatment of melasma

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100042958
Enrollment
Unknown
Registered
2021-02-01
Start date
2020-11-04
Completion date
Unknown
Last updated
2021-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

melasma

Interventions

Group A:hydroquinone+picosecond laser
Group B:microneedle+picosecond laser

Sponsors

Beijing Friendship Hospital affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Female patients aged 18-60 years; 2. The patients with melasma and symmetrical facial rash were diagnosed; 3. The facial skin was basically intact without obvious inflammation, ulceration and exudation; 4. Those who have not received any treatment (including laser, oral medication) in the past 6 months; 5. No history of sun exposure in recent 3 months; 6. Good compliance and regular follow-up.

Exclusion criteria

Exclusion criteria: 1. Patients with severe cardiovascular and cerebrovascular diseases, liver and kidney diseases, hematopoietic system diseases, mental diseases and immunodeficiency diseases; 2. Pregnant or lactating women; 3. Allergic to the test drug and its components; 4. Researchers participating in other clinical trials; 5. The researcher thinks that it is not suitable to participate in this research.

Design outcomes

Primary

MeasureTime frame
Melasma area severity index;

Secondary

MeasureTime frame
Reflectance confocal microscopy;

Countries

China

Contacts

Public ContactZhuo Fenglin

Beijing Friendship Hospital affiliated to Capital Medical University

770972657@qq.com+86 15910895068

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026